Your gut microbiome is secretly running a hormone factory that controls digestion

Deep in the gut, something far more specific than generic "fermentation" appears to be happening. A study published June 2026 in Nature Neuroscience suggests that gut bacteria actively reactivate androgens like DHT and testosterone inside the intestinal lumen, and that those hormones then instruct a specific class of neurons to regulate how fast the colon moves. The findings add a striking new dimension to our understanding of the gut-brain axis, and raise pointed questions about why some men experience unexplained bowel problems.

Bacterial enzyme beta-glucuronidase reactivates androgens in the colon

Androgens circulate through the body in inactivated, conjugated forms. When they reach the gut, certain bacteria produce an enzyme called beta-glucuronidase (GUS) that strips a chemical tag off these inactive compounds, converting them back into their bioavailable forms: active DHT and testosterone. The study found that free DHT levels in the distal intestine actually exceed blood serum concentrations, and that this local surplus is entirely dependent on microbial activity. When the researchers removed gut bacteria from mice, DHT in the intestinal lumen fell sharply and transit slowed. Infusing a single GUS enzyme was enough to restore the signaling. Gut microbes have long been known to metabolize sex hormones through beta-glucuronidase activity, but this study identifies exactly where those reactivated hormones land and what they do next.

Inhibitory motor neurons in the colon are the direct targets

The researchers traced the hormonal signal to a specific neuronal population: NOS1-positive inhibitory motor neurons embedded in the gut wall. These neurons directly control the speed of colon contractions. About 95% of androgen-receptor-positive enteric neurons in male mice turned out to be NOS1+ inhibitory motor neurons, making them the overwhelming cellular target of locally reactivated androgens. When androgen signaling was disrupted, colon transit slowed measurably. The picture that emerges is precise: bacteria produce GUS, GUS liberates active DHT, DHT binds NOS1+ neurons, and those neurons modulate the pace of intestinal movement. It is a tight mechanistic chain, not a vague correlation.

Why these findings matter most for men with unexplained GI problems

Because androgens are typically at higher levels in males, the motility effects in this study were observed primarily in male mice. Female murine colons showed minimal impact from androgen signaling along this pathway. That sex difference could help explain a subset of poorly understood GI complaints in men, particularly cases where standard diagnostics turn up nothing. The concept of the "microgenderome," the idea that the gut microbiome and sex hormones interact in sex-specific ways, has been gaining traction for several years. Research has already tied microbiome dysbiosis to reproductive health disorders including impaired spermatogenesis, and separate work has documented how sex hormones and gut microbiota jointly influence metabolic diseases like obesity and type 2 diabetes with pronounced sex-based differences. This new study adds bowel motility to that list, and does so with unusually sharp mechanistic detail.

How germ-free animals and enzyme infusions confirmed the mechanism

The team used several converging methods to establish causality rather than association. Stripping mice of their gut bacteria slowed colon transit, implicating the microbiome directly. Restoring the system with a single GUS enzyme, rather than full microbial recolonization, was sufficient to rescue the signaling, which isolated beta-glucuronidase as the critical molecular step. The researchers also confirmed the identity of the target neurons, finding that roughly 95% of androgen-receptor-positive enteric neurons in male mice carry the NOS1 marker. Early studies using germ-free animal models and cell-level observations have historically been central to mapping hormone-microbiota interactions, and this study follows that methodological tradition while pushing the resolution down to the level of individual enzyme activity and named neuron types.

Open questions about female physiology and clinical translation

The study's most significant limitation is also one of its most interesting features: the effect was essentially absent in female mice. Whether this reflects lower baseline androgen levels, different neuronal receptor densities, or some other sex-specific variable is not yet clear. Translating the male-specific findings to human physiology will require direct investigation in people, not just rodents. The authors also note that any intervention touching the microbiome, whether antibiotics, a major dietary shift, or a microbiota transplant, could inadvertently disrupt this androgen-reactivation circuit, with potentially real consequences for GI motility. That is a clinically practical warning: it suggests practitioners may need to factor in the microbiome's endocrine role when patients report motility changes after antibiotic courses or significant dietary changes.

What the gut-as-hormone-factory model could mean for treatment

If the gut microbiome is functioning as a local hormone factory rather than just a digestive aid, that reframes how researchers might approach motility disorders. A man with slow colon transit and a depleted GUS-producing microbial community might benefit from targeted microbiome intervention rather than, or alongside, motility drugs. Conversely, conditions driven by androgen excess could potentially be worsened by microbial communities with unusually high GUS activity. Neither scenario is clinical guidance yet: these are emerging findings, not established treatment frameworks. But the mechanistic specificity here, a named enzyme, a named neuron type, a measurable hormonal concentration, gives future researchers concrete handles to test. That kind of molecular precision is what turns interesting biology into tractable medicine.

Evidence rating

EMERGING — 78/100

Caveats:

• Findings are based primarily on male mice; androgen signaling showed minimal effect on female murine colons, and direct human translation has not yet been established.
• Funding source was not disclosed in the available record; independent replication has not yet been published.
• Animal-to-human extrapolation is not guaranteed — gut androgen concentrations and enteric neuron biology may differ meaningfully between species.

This study used male and female mouse models to demonstrate a specific mechanistic pathway in which bacterial beta-glucuronidase reactivates conjugated androgens in the gut lumen, which then signal NOS1+ inhibitory motor neurons to control colonic transit. The findings establish a causal chain within animal models but have not yet been replicated in independent laboratories or validated in human subjects. Motility effects were observed predominantly in male mice, limiting generalizability, and the study represents a single mechanistic investigation without direct clinical data.